382 related articles for article (PubMed ID: 28085177)
1. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
2. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Amin C; Wallen E; Pruthi RS; Calvo BF; Godley PA; Rathmell WK
Urology; 2008 Oct; 72(4):864-8. PubMed ID: 18684493
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
[TBL] [Abstract][Full Text] [Related]
4. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.
Nunez Bragayrac L; Hoffmeyer J; Abbotoy D; Attwood K; Kauffman E; Spiess P; Wagner A; Schwaab T
World J Urol; 2016 Dec; 34(12):1651-1656. PubMed ID: 27084776
[TBL] [Abstract][Full Text] [Related]
5. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
6. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
8. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
9. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
[TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
11. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
12. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
13. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
14. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
15. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.
Bölükbas S; Kudelin N; Eberlein M; Fisseler-Eckhoff A; Schirren J
Thorac Cardiovasc Surg; 2012 Sep; 60(6):390-7. PubMed ID: 22207364
[TBL] [Abstract][Full Text] [Related]
16. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
17. Choice of Surgical Options in Kidney Cancer and Surgical Complications.
Wasserman M; Sobel D; Pareek G
Semin Nephrol; 2020 Jan; 40(1):42-48. PubMed ID: 32130965
[TBL] [Abstract][Full Text] [Related]
18. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
[TBL] [Abstract][Full Text] [Related]
19. Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy.
Carvalho FLF; Zheng C; Witmer K; O'neill J; Lynch JH; Kowalczyk KJ
Sci Rep; 2019 Oct; 9(1):15272. PubMed ID: 31649310
[TBL] [Abstract][Full Text] [Related]
20. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
